Answers are grounded in this paper and cite their sources.
Monitoring immunosuppressive drugs (ISDs) in blood or plasma is still a key therapeutic drug monitoring (TDM) application in clinical settings. Narrow target ranges and severe side effects at drug underexposure or overexposure make accurate and precise measurements a must. This overview prepared by the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology is intended to serve as a summary and guidance document describing the current state-of-the-art in the TDM of ISDs.
No takes yet. Share an insight, caveat, or question.
Shipkova et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: